id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-V-6101-0003,FDA,FDA-2019-V-6101,Letter from FDA CDRH to Donovan Rosling,Other,Letter(s),2020-02-06T05:00:00Z,2020,2,2020-02-06T05:00:00Z,,2020-02-06T15:30:49Z,,0,0,0900006484334a2e